**
Recent research indicates that a significant number of breast cancer patients could potentially forgo chemotherapy, thanks to a pioneering DNA test designed to identify those unlikely to benefit from this intensive treatment. Conducted by an international team led by University College London (UCL), the study assessed over 4,000 newly diagnosed patients and revealed that more than two-thirds of participants could be treated effectively with hormone therapy alone, sparing them from the harsh side effects associated with chemotherapy.
The Study’s Findings
The trial involved patients aged 40 and older from the UK, Norway, Sweden, Australia, New Zealand, and Thailand. Researchers utilised a gene expression test known as Prosigna, which evaluates the activity of 50 genes linked to breast cancer progression. This analysis allowed them to stratify patients based on their risk of cancer recurrence. Remarkably, two-thirds of the study’s participants received a low-risk score, indicating that chemotherapy would not provide significant benefits for them.
Data from the study showed that the five-year survival rate for patients who avoided chemotherapy was 93.7%, only slightly lower than the 94.9% survival rate for those who did undergo chemotherapy. Such findings suggest that many women may be subject to unnecessary treatment, prompting concerns among clinicians about the effectiveness of chemotherapy for the most prevalent types of breast cancer.
Implications for Treatment Protocols
Typically, surgery is the first line of treatment for breast cancer, with chemotherapy often recommended post-operatively to reduce the risk of recurrence. However, the UCL study highlights a shift in thinking regarding the necessity of chemotherapy for early-stage breast cancer, particularly in cases where the cancer has spread to nearby lymph nodes. This evolution in treatment paradigms could lead to a significant reduction in the number of patients receiving chemotherapy, with estimates suggesting that more than 5,000 patients in the NHS could be spared this treatment annually.
Karen Bonham, a participant in the trial, shared her relief at being able to avoid chemotherapy, stating that the results felt like “Christmas.” At 64, Bonham has been managing her breast cancer for eight years with radiotherapy and hormone therapy, expressing the emotional toll a cancer diagnosis can take on one’s life priorities.
Expert Opinions on the Findings
Professor David Miles, a prominent cancer specialist involved in the study, emphasised the transformative nature of these findings, calling them “practice-changing.” He noted that the ability to predict which patients will not benefit from chemotherapy allows for more tailored treatment plans. “We used to give chemotherapy to 100 women to benefit 10, knowing that 90 didn’t need it,” he remarked. This shift could not only improve patient quality of life but also optimise healthcare resources.
Tanya Hutson, diagnosed with breast cancer in 2022, described the new DNA test as “absolutely amazing,” highlighting the importance of research funding in developing such innovative solutions. Her experience with chemotherapy was notably harsh, and she believes the test can change lives by preventing unnecessary treatment for patients who do not need it.
Future Considerations
While the study’s results are promising, there remains a significant gap in understanding the test’s applicability for individuals under the age of 40, with further research needed before definitive recommendations can be made. As this field of research evolves, the emphasis will be on refining patient selection to ensure optimal treatment pathways are established.
Why it Matters
The implications of this study extend beyond individual patient care; they herald a potential paradigm shift in the treatment of breast cancer. By identifying patients who can safely avoid the rigours of chemotherapy, this research paves the way for more personalised, less invasive treatment options. This could not only enhance the quality of life for countless individuals but also contribute to a more efficient healthcare system by redirecting resources toward those who truly need intensive therapies. As we continue to advance our understanding of cancer treatment, the focus must remain on ensuring that patients receive the most effective care tailored to their specific circumstances.
